NO-cGMP-K channel-dependent anti-nociceptive activities of methanol stem bark extract of Piptadeniastrum africanum (Mimosaceae) on rats

Mbiantcha, Marius; Jabeen, Almas; Ateufack, Gilbert; Simjee, Shabana Usman; Bomba, Francis Desire Tatsinkou; Dastagir, Nida

doi:10.4103/2221-1691.227996

Cited by 5 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subplantar injection of carrageenan significantly increased paw thickness at 1, 2, 3, 4, and 24 h after injection, which is in agreement with previous studies [40,41]. The control carrageenan-treated group also showed a significant decrease in the nociceptive threshold, which is in accordance with previous results [19,42]. The indomethacin-pretreated group showed a significant reduction in increased paw thickness produced by carrageenan, which is in agreement with Uzkeser et al [43] and Okhuarobo and Ozolua [44].…”

Section: The Direct Assessment Of Antiinflammatory and Analgesic Effectssupporting

confidence: 92%

See 1 more Smart Citation

Standardized study of atorvastatin possible osteoarthritis disease‐modifying effect in a rat model of osteoarthritis

Gaballah

Genedy

Ghayaty

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

We studied the osteoarthritis (OA)-modifying effects of atorvastatin in an experimental OA rat model and possible underlining mechanisms. We used 62 adult male Sprague-Dawley rats (250-300 g): 32 rats were used to assess the effects of atorvastatin on surgically induced OA in the knee, and 30 rats were used to assess the potential inflammatory effects of carrageenan-induced paw edema. In the OA model, joint stiffness was assessed by measuring the knee extension angle, and pathological changes in the OA knee joint were determined by histological examination and the measurement of serum biochemical markers, including interleukin-1β (IL-1β), matrix metalloproteinase-13 (MMP-13), and reduced glutathione (GSH). In the carrageenan-induced paw edema model, both paw thickness and pain threshold were assessed in different groups. Atorvastatin significantly improved joint stiffness, pathological changes, a significant mitigation of the higher MMP-13 and IL-1β, and a significant increase of reduced GSH in OA rats. Additionally, atorvastatin significantly improved both paw thickness and pain threshold in animals. Atorvastatin is a potential OA-modifying drug that warrants further clinical investigation.

show abstract

Section: The Direct Assessment Of Antiinflammatory and Analgesic Effectssupporting

confidence: 92%

“…The nociceptive threshold was taken as the point at which the rat vocalized or struggled vigorously and was expressed as force in grams (g). The nociceptive threshold (g) was recorded at 1, 2, 3, 4, and 24 h after carrageenan injection [19].…”

Section: Recording Pain Thresholdmentioning

confidence: 99%

Standardized study of atorvastatin possible osteoarthritis disease‐modifying effect in a rat model of osteoarthritis

Gaballah

Genedy

Ghayaty

et al. 2021

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…These results came in agreement with Sadeghi et al, 2014 andAntonisamy et al, 2017. The carrageenan-treated group also showed a significant decrease in the nociceptive threshold that was parallel with Kuedo et al, 2016;Marius et al, 2018. The indomethacin treated group showed a significant reduction of the increased paw thickness produced by carrageenan in agreement with Uzkeser et al, 2012 andOkhuarobo andOzolua, 2017.…”

Section: Discussionsupporting

confidence: 81%

“…The nociceptive threshold was taken as the point at which the rat vocalized or struggled vigorously, expressed as the force in grams (g). The nociceptive threshold (g) was recorded at 1, 2, 3, 4 h, and 24h after carrageenan injection (Marius et al, 2018).…”

Section: Recording Of Pain Thresholdmentioning

confidence: 99%

Standardized Study of Atorvastatin Possible Osteoarthritis Disease-Modifying Effect in Rats

Gaballah

Genedy

Ghayaty

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and purpose: Osteoarthritis (OA) is a chronic and progressive joint disorder characterized by structural damage to one or more joints. However, drugs that could cure or at least stop the progression of this disease are still given no satisfactory outcome. The purpose of this work is to study the potential OA disease-modifying effects of atorvastatin in an experimental model of osteoarthritis and the possible underlining mechanisms if any. Experimental Approach: Seventy-six adult male Sprague-Dawley rats (250-300gms) were used throughout this study. Forty rats were used to assess the effect of atorvastatin in surgically induced OA. While 36 rats were used to assess its anti-inflammatory effect in carrageenan-induced paw edema. In the model of OA; the degree of joint stiffness was assessed by measuring the angle of knee extension besides, the histopathological changes of the OA knee joints and measurement of serum Interleukin-1beta (IL-1β), Matrix metalloproteinase-13 (MMP13), and reduced glutathione (GSH) concentration were biochemically assessed. In the carrageenan-induced paw edema, the paw thickness and pain threshold were assessed in different groups. Key Results: Atorvastatin was found to produce significant improvement of joint stiffness, the histopathological changes, a significant correction in the increased MMP13 and IL1-β, and the decreased GTH in OA rats. Also, atorvastatin showed a significant improvement in both paw thickness and pain threshold. Conclusion and ImplicationsThese results present atorvastatin as OA disease-modifying drug worse clinical trials.

show abstract

“…At the center of the hind paw, pressure was applied in a linearly increasing fashion. PAM records the pressure (expressed in grams) which induces the paw withdrawal response …”

Section: Methodsmentioning

confidence: 99%

Bergapten Ameliorates Vincristine-Induced Peripheral Neuropathy by Inhibition of Inflammatory Cytokines and NFκB Signaling

Singh

et al. 2019

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Bergapten, a furanocoumarin derivative found in a variety of medicinal plants, is documented to possess anti-inflammatory activity. However, whether bergapten is useful in alleviating the symptoms as well as the progress of peripheral neuropathy is not yet studied. The current investigation has been designed to explore the effect of bergapten on vincristine-induced neuropathic pain. Rats were grouped as normal, neuropathic control (vincristine), gabapentin, and bergapten treated groups with five animals in each group. Vincristine (100 μg/kg, i.p.) was administered for 10 days with 2 days break. Gabapentin (60 mg/kg, i.p.) and bergapten (10 mg/kg i.p.) treatments were given once daily for 14 days. The animals were assessed for hyperalgesia and allodynia. After 14 days, animals were sacrificed to detect plasma pro-inflammatory cytokines (TNF α, IL-1β), spinal cord, and sciatic nerve oxidative stress and expression of iNOS, COX-2, and NFkB in the spinal cord. There was a marked reduction in pain behaviors in the bergapten group as compared to the vincristine group. Bergapten also attenuated pro-inflammatory cytokines (TNFα and IL-1β), oxidative stress, and expression of NFkB, COX-2, and iNOS. Overall the current study concludes that bergapten could serve as a potential lead to drug development for the treatment of neuropathic pain.

show abstract

NO-cGMP-K channel-dependent anti-nociceptive activities of methanol stem bark extract of Piptadeniastrum africanum (Mimosaceae) on rats

Cited by 5 publications

References 8 publications

Standardized study of atorvastatin possible osteoarthritis disease‐modifying effect in a rat model of osteoarthritis

Standardized study of atorvastatin possible osteoarthritis disease‐modifying effect in a rat model of osteoarthritis

Standardized Study of Atorvastatin Possible Osteoarthritis Disease-Modifying Effect in Rats

Bergapten Ameliorates Vincristine-Induced Peripheral Neuropathy by Inhibition of Inflammatory Cytokines and NFκB Signaling

Contact Info

Product

Resources

About